Breast Cancer Survival Rates by Stage

What survival statistics mean

Five-year survival rates describe the percentage of people alive five years after a breast cancer diagnosis, based on large population datasets compiled from the UK's Office for National Statistics (ONS). They are population averages — individual outcomes depend on many factors including tumour characteristics, general health, and treatment response. A high survival rate is not a guarantee; a lower one is not a verdict.

UK five-year survival by stage (NHS/ONS)

• Stage 1 — small tumour (up to 2cm), no lymph node spread: approximately 98% five-year survival
• Stage 2 — tumour 2–5cm and/or limited lymph node involvement: approximately 90% five-year survival
• Stage 3 — locally advanced, significant lymph node or chest wall involvement: approximately 70% five-year survival
• Stage 4 — secondary/metastatic breast cancer, spread to distant organs: approximately 26% five-year survival

Why survival has improved so dramatically

UK breast cancer survival has more than doubled over the past 40 years — from around 40% in the 1970s to over 85% today. The main drivers are: the introduction of NHS mammography screening in 1988 (shifting more diagnoses to earlier stages); the development of targeted therapies such as trastuzumab (Herceptin) for HER2-positive disease; improved hormone therapies for ER-positive disease; and better surgical and radiotherapy techniques.

Survival by cancer subtype

• Hormone receptor-positive (ER+) breast cancer: generally good prognosis; five to ten years of hormone therapy (tamoxifen or an aromatase inhibitor) significantly reduces recurrence risk
• HER2-positive breast cancer: previously poor prognosis, now greatly improved with trastuzumab and other HER2-targeted drugs — survival has roughly doubled since Herceptin was introduced
• Triple-negative breast cancer (TNBC): tends to be more aggressive, but responds well to chemotherapy when it does respond; immunotherapy (pembrolizumab) is further improving outcomes for high-risk early TNBC

The global survival gap

While UK five-year survival exceeds 85%, the equivalent figure in low-income countries can be below 40%. This is not primarily a biological difference — it is structural. In countries without population screening programmes, most breast cancers are found at Stage III or IV. In Pakistan, Bangladesh and Indonesia — the countries where Breast Cancer Awareness works — late-stage diagnosis is the norm rather than the exception. Improving access to early detection in these countries is the most cost-effective way to save lives.

Living with Stage 4 breast cancer

The five-year survival figure for Stage 4 (secondary) breast cancer — approximately 26% — is a population average and has been rising steadily. Many people live well beyond five years. New treatments including CDK4/6 inhibitors (palbociclib, ribociclib), antibody-drug conjugates (trastuzumab deruxtecan), PARP inhibitors (olaparib) and immunotherapy have significantly extended survival for specific patient groups. Secondary breast cancer is increasingly managed as a long-term condition.